Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
V Launay-Vacher, JB Rey, C Isnard-Bagnis… - Cancer chemotherapy …, 2008 - Springer
V Launay-Vacher, JB Rey, C Isnard-Bagnis, G Deray, M Daouphars
Cancer chemotherapy and pharmacology, 2008•SpringerAntineoplastic drugs used in the treatment of cancers present with variable renal tolerance
profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially
cisplatin is a well-known agent that may induce acute and chronic renal failure. The
mechanisms of its renal toxicity and the means of its prevention are presented in this article
which represent the Clinical Recommendation from the Special Interest Group on Cancer
Care of the European Society of Clinical Pharmacy (ESCP).
profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially
cisplatin is a well-known agent that may induce acute and chronic renal failure. The
mechanisms of its renal toxicity and the means of its prevention are presented in this article
which represent the Clinical Recommendation from the Special Interest Group on Cancer
Care of the European Society of Clinical Pharmacy (ESCP).
Abstract
Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).
Springer